Burning Rock Biotech Limited income statement BNR
In fiscal 2025, which ended Dec 31, 2025, Burning Rock Biotech Limited reported revenue of $77.2 million, up 9.2% from the year before. It recorded a net loss of $7.9 million. The operating loss came to $7.8 million, an operating margin of -10.2%. Across the 6 fiscal years shown, revenue grew from $65.9 million in fiscal 2020 to $77.2 million in fiscal 2025, about 3.2% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
|---|---|---|---|---|---|---|
| Revenue |
77
+9.2%
|
71
-6.6%
|
76
-7.3%
|
82
+2.5%
|
80
+21.0%
|
66
|
| Cost of revenue |
20
-7.0%
|
21
-14.3%
|
25
-7.6%
|
27
+17.8%
|
23
+26.9%
|
18
|
| Gross profit |
58
+16.0%
|
50
-3.0%
|
51
-7.2%
|
55
-3.6%
|
57
+18.8%
|
48
|
| Research and development |
24
-25.2%
|
32
-34.9%
|
49
-20.1%
|
61
+6.0%
|
58
+42.7%
|
40
|
| Selling, general and administrative |
42
-32.8%
|
62
-35.8%
|
97
-29.0%
|
136
+9.3%
|
124
+75.7%
|
71
|
| Operating expenses |
65
|
—
|
145
-26.3%
|
197
+8.2%
|
182
+63.7%
|
111
|
| Operating income |
-8
+84.0%
|
-49
+48.0%
|
-94
+33.7%
|
-142
-13.6%
|
-125
-97.9%
|
-63
|
| Pretax income |
-8
+83.5%
|
-47
+49.1%
|
-92
+34.7%
|
-141
-12.5%
|
-125
-100.1%
|
-62
|
| Income tax |
0
-72.3%
|
1
+139.9%
|
0
+16.7%
|
0
+104.3%
|
0
|
0
|
| Net income |
-8
+83.3%
|
-47
+48.4%
|
-92
+34.6%
|
-141
-12.6%
|
-125
-100.3%
|
-62
|
| Other measures | ||||||
| Depreciation and amortization |
3
-56.5%
|
7
-61.9%
|
19
+4.4%
|
18
+140.0%
|
7
+46.8%
|
5
|
| EBITDA |
-5
+88.7%
|
-42
+44.6%
|
-75
+39.2%
|
-124
-5.6%
|
-118
-102.4%
|
-58
|
| Interest coverage |
—
|
—
|
—
|
—
|
-519.00x
|
-619.66x
|
| Margins | ||||||
| Gross margin |
74.67%
|
70.25%
|
67.58%
|
67.47%
|
71.70%
|
73.02%
|
| Operating margin |
-10.17%
|
-69.32%
|
-124.54%
|
-174.07%
|
-156.95%
|
-95.93%
|
| Pretax margin |
-9.97%
|
-66.06%
|
-121.19%
|
-172.08%
|
-156.70%
|
-94.73%
|
| Profit margin |
-10.26%
|
-67.20%
|
-121.63%
|
-172.44%
|
-156.88%
|
-94.73%
|
| EBITDA margin |
-6.13%
|
-59.20%
|
-99.72%
|
-152.03%
|
-147.54%
|
-88.18%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BNR (Nasdaq)
- Headquarters
- Guangzhou, Guangdong
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1792267
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.